Navarixin (MK‐7123), a CXCR2/CXCR1 antagonist with oral bioavailability, is currently evaluated in clinical trials for its efficacy and safety in advanced/metastatic solid tumors, psoriasis, and COPD (NCT03473925, NCT00684593, NCT00688467, and NCT01006616). Here, CXCR2 is linked to chronic obstructive pulmonary disease.